371 related articles for article (PubMed ID: 11356703)
21. The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives.
Menéndez JA; Mehmi I; Griggs DW; Lupu R
Endocr Relat Cancer; 2003 Jun; 10(2):141-52. PubMed ID: 12790776
[TBL] [Abstract][Full Text] [Related]
22. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF.
Filardo EJ; Quinn JA; Bland KI; Frackelton AR
Mol Endocrinol; 2000 Oct; 14(10):1649-60. PubMed ID: 11043579
[TBL] [Abstract][Full Text] [Related]
23. Up-regulation of LRP16 mRNA by 17beta-estradiol through activation of estrogen receptor alpha (ERalpha), but not ERbeta, and promotion of human breast cancer MCF-7 cell proliferation: a preliminary report.
Han WD; Mu YM; Lu XC; Xu ZM; Li XJ; Yu L; Song HJ; Li M; Lu JM; Zhao YL; Pan CY
Endocr Relat Cancer; 2003 Jun; 10(2):217-24. PubMed ID: 12790785
[TBL] [Abstract][Full Text] [Related]
24. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha.
Kinoshita Y; Chen S
Cancer Res; 2003 Jul; 63(13):3546-55. PubMed ID: 12839940
[TBL] [Abstract][Full Text] [Related]
25. Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth factors.
Ram PT; Kiefer T; Silverman M; Song Y; Brown GM; Hill SM
Mol Cell Endocrinol; 1998 Jun; 141(1-2):53-64. PubMed ID: 9723886
[TBL] [Abstract][Full Text] [Related]
26. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.
Millour J; Constantinidou D; Stavropoulou AV; Wilson MS; Myatt SS; Kwok JM; Sivanandan K; Coombes RC; Medema RH; Hartman J; Lykkesfeldt AE; Lam EW
Oncogene; 2010 May; 29(20):2983-95. PubMed ID: 20208560
[TBL] [Abstract][Full Text] [Related]
27. Estrogen and phorbol esters regulate amphiregulin expression by two separate mechanisms in human breast cancer cell lines.
Martínez-Lacaci I; Saceda M; Plowman GD; Johnson GR; Normanno N; Salomon DS; Dickson RB
Endocrinology; 1995 Sep; 136(9):3983-92. PubMed ID: 7649107
[TBL] [Abstract][Full Text] [Related]
28. Estrogen upregulation of BRCA1 expression with no effect on localization.
Romagnolo D; Annab LA; Thompson TE; Risinger JI; Terry LA; Barrett JC; Afshari CA
Mol Carcinog; 1998 Jun; 22(2):102-9. PubMed ID: 9655254
[TBL] [Abstract][Full Text] [Related]
29. Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies.
Tsai MS; Hornby AE; Lakins J; Lupu R
Cancer Res; 2000 Oct; 60(20):5603-7. PubMed ID: 11059746
[TBL] [Abstract][Full Text] [Related]
30. Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients.
Karam M; Bièche I; Legay C; Vacher S; Auclair C; Ricort JM
J Cell Mol Med; 2014 Dec; 18(12):2536-52. PubMed ID: 25287328
[TBL] [Abstract][Full Text] [Related]
31. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells.
Fan M; Bigsby RM; Nephew KP
Mol Endocrinol; 2003 Mar; 17(3):356-65. PubMed ID: 12554766
[TBL] [Abstract][Full Text] [Related]
32. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract][Full Text] [Related]
33. Hypoxia reduces hormone responsiveness of human breast cancer cells.
Kurebayashi J; Otsuki T; Moriya T; Sonoo H
Jpn J Cancer Res; 2001 Oct; 92(10):1093-101. PubMed ID: 11676860
[TBL] [Abstract][Full Text] [Related]
34. C-myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells.
Venditti M; Iwasiow B; Orr FW; Shiu RP
Int J Cancer; 2002 May; 99(1):35-42. PubMed ID: 11948489
[TBL] [Abstract][Full Text] [Related]
35. Regulation of estrogen receptor messenger ribonucleic acid and protein levels in human breast cancer cell lines by sex steroid hormones, their antagonists, and growth factors.
Read LD; Greene GL; Katzenellenbogen BS
Mol Endocrinol; 1989 Feb; 3(2):295-304. PubMed ID: 2785242
[TBL] [Abstract][Full Text] [Related]
36. A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro.
Kurebayashi J; Otsuki T; Yamamoto S; Kurosumi M; Nakata T; Akinaga S; Sonoo H
Oncology; 1998 Dec; 55 Suppl 1():23-34. PubMed ID: 9852399
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.
Osborne CK; Coronado-Heinsohn EB; Hilsenbeck SG; McCue BL; Wakeling AE; McClelland RA; Manning DL; Nicholson RI
J Natl Cancer Inst; 1995 May; 87(10):746-50. PubMed ID: 7563152
[TBL] [Abstract][Full Text] [Related]
38. Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation.
Lin MT; Chang CC; Chen ST; Chang HL; Su JL; Chau YP; Kuo ML
J Biol Chem; 2004 Jun; 279(23):24015-23. PubMed ID: 15044484
[TBL] [Abstract][Full Text] [Related]
39. Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family.
Larsen SS; Egeblad M; Jäättelä M; Lykkesfeldt AE
Breast Cancer Res Treat; 1999 Nov; 58(1):41-56. PubMed ID: 10634517
[TBL] [Abstract][Full Text] [Related]
40. Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7.
Diel P; Olff S; Schmidt S; Michna H
J Steroid Biochem Mol Biol; 2002 Jan; 80(1):61-70. PubMed ID: 11867264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
